ChromaDex, Inc. v. Elysium Health, Inc., No. 22-1116 (Fed. Cir. Feb. 13, 2023)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

ChromaDex, Inc. (“ChromaDex”) and the Trustees of Dartmouth College (“Dartmouth”) (collectively, “Appel- lants”) appeal the decision of the U.S. District Court for the District of Delaware granting Elysium Health, Inc.’s (“Ely- sium”) motion for summary judgment that the asserted claims of U.S. Patent No. 8,197,807 (“the ’807 patent”) are directed to unpatentable subject matter under 35 U.S.C. § 101.1 We affirm.